You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEverolimus
Accession NumberDB01590
TypeSmall Molecule
GroupsApproved
DescriptionEverolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Structure
Thumb
Synonyms
40-O-(2-hydroxyethyl)-rapamycin
External Identifiers
  • RAD 666
  • RAD-001
  • RAD-666
  • RAD001
  • SDZ RAD
  • SDZ-RAD
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AfinitorTablet10 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
Afinitortablet10 mgoralNovartis Pharmaceuticals Canada Inc2010-01-19Not applicableCanada
AfinitorTablet2.5 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
Afinitortablet10 mg/1oralNovartis Pharmaceuticals Corporation2009-03-31Not applicableUs
Afinitortablet7.5 mgoralNovartis Pharmaceuticals Canada Inc2016-04-05Not applicableCanada
AfinitorTablet10 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
Afinitortablet2.5 mgoralNovartis Pharmaceuticals Canada Inc2011-08-05Not applicableCanada
AfinitorTablet2.5 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
Afinitortablet2.5 mg/1oralNovartis Pharmaceuticals Corporation2010-07-09Not applicableUs
AfinitorTablet5 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
AfinitorTablet5 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
AfinitorTablet5 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
Afinitortablet7.5 mg/1oralNovartis Pharmaceuticals Corporation2011-07-29Not applicableUs
Afinitortablet5 mgoralNovartis Pharmaceuticals Canada Inc2010-03-15Not applicableCanada
AfinitorTablet10 mgOral useNovartis Europharm Limited2009-08-03Not applicableEu
Afinitortablet5 mg/1oralNovartis Pharmaceuticals Corporation2009-03-31Not applicableUs
Afinitor Disperztablet, for suspension2 mg/1oralNovartis Pharmaceuticals Corporation2012-08-29Not applicableUs
Afinitor Disperztablet for suspension5 mgoralNovartis Pharmaceuticals Canada Inc2014-11-28Not applicableCanada
Afinitor Disperztablet, for suspension3 mg/1oralNovartis Pharmaceuticals Corporation2012-08-29Not applicableUs
Afinitor Disperztablet, for suspension5 mg/1oralNovartis Pharmaceuticals Corporation2012-08-29Not applicableUs
Afinitor Disperztablet for suspension2 mgoralNovartis Pharmaceuticals Canada Inc2014-11-28Not applicableCanada
Afinitor Disperztablet for suspension3 mgoralNovartis Pharmaceuticals Canada Inc2014-11-28Not applicableCanada
Certicantablet0.25 mgoralNovartis Pharmaceuticals Canada IncNot applicableNot applicableCanada
Certicantablet0.50 mgoralNovartis Pharmaceuticals Canada IncNot applicableNot applicableCanada
Certicantablet0.75 mgoralNovartis Pharmaceuticals Canada IncNot applicableNot applicableCanada
VotubiaDispersible Tablet2 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet2.5 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaDispersible Tablet5 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet10 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaDispersible Tablet2 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet5 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaDispersible Tablet5 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet10 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaDispersible Tablet3 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet5 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet2.5 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaDispersible Tablet2 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaDispersible Tablet3 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet10 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
VotubiaTablet2.5 mgOral useNovartis Europharm Ltd2011-09-02Not applicableEu
Zortresstablet.5 mg/1oralNovartis Pharmaceuticals Corporation2010-04-22Not applicableUs
Zortresstablet.75 mg/1oralNovartis Pharmaceuticals Corporation2010-04-22Not applicableUs
Zortresstablet.25 mg/1oralNovartis Pharmaceuticals Corporation2010-04-22Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VotubiaNovartis
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9HW64Q8G6G
CAS number159351-69-6
WeightAverage: 958.24
Monoisotopic: 957.581356357
Chemical FormulaC53H83NO14
InChI KeyHKVAMNSJSFKALM-GKUWKFKPSA-N
InChI
InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
IUPAC Name
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
SMILES
[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[[email protected]](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[[email protected]](C)C[[email protected]](C)\C=C\C=C\C=C(C)\[[email protected]](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Alpha-amino acid ester
  • Macrolide
  • Alpha-amino acid or derivatives
  • Piperidine
  • Oxane
  • Tertiary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid ester
  • Hemiacetal
  • Ketone
  • Lactam
  • Cyclic ketone
  • Secondary alcohol
  • Lactone
  • Carboxylic acid derivative
  • Dialkyl ether
  • Ether
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Carbonyl group
  • Organic oxide
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
PharmacodynamicsNot Available
Mechanism of actionEverolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake.
Related Articles
AbsorptionIn patients with advanced solid tumors, peak everolimus concentrations are reached 1 to 2 hours after administration of oral doses ranging from 5 mg to 70 mg. Following single doses, Cmax is dose-proportional between 5 mg and 10 mg. At doses of 20 mg and higher, the increase in Cmax is less than dose-proportional, however AUC shows dose-proportionality over the 5 mg to 70 mg dose range. Steady-state was achieved within 2 weeks following once-daily dosing. Dose Proportionality in Patients with SEGA (subependymal giant-cell astrocytomas) and TSC (tuberous sclerosis complex): In patients with SEGA and TSC, everolimus Cmin was approximately dose-proportional within the dose range from 1.35 mg/m2 to 14.4 mg/m2.
Volume of distribution

The blood-to-plasma ratio of everolimus is 17% to 73%.

Protein binding~ 74% in both healthy patients and those with moderate hepatic impairment.
Metabolism

Everolimus is a substrate of CYP3A4 and PgP (phosphoglycolate phosphatase). Three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus were the 6 primary metabolites detected in human blood. In vitro, everolimus competitively inhibited the metabolism of CYP3A4 and was a mixed inhibitor of the CYP2D6 substrate dextromethorphan.

Route of eliminationAfter a single dose of radiolabeled everolimus was given to transplant patients receiving cyclosporine, the majority (80%) of radioactivity was recovered from the feces and only a minor amount (5%) was excreted in urine.
Half life~30 hours.
Clearance

Following a 3 mg radiolabeled dose of everolimus, 80% of the radioactivity was recovered from the feces, while 5% was excreted in the urine.

ToxicityIC50 of 0.63 nM.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8288
Blood Brain Barrier-0.9541
Caco-2 permeable-0.6604
P-glycoprotein substrateSubstrate0.8117
P-glycoprotein inhibitor IInhibitor0.7789
P-glycoprotein inhibitor IIInhibitor0.7294
Renal organic cation transporterNon-inhibitor0.796
CYP450 2C9 substrateNon-substrate0.8793
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9078
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9388
CYP450 2C19 inhibitorNon-inhibitor0.9346
CYP450 3A4 inhibitorNon-inhibitor0.8168
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9734
Ames testNon AMES toxic0.6227
CarcinogenicityNon-carcinogens0.9362
BiodegradationNot ready biodegradable0.9257
Rat acute toxicity2.7442 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9776
hERG inhibition (predictor II)Non-inhibitor0.712
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral10 mg
Tabletoral2.5 mg/1
Tabletoral2.5 mg
Tabletoral5 mg/1
Tabletoral5 mg
Tabletoral7.5 mg/1
Tabletoral7.5 mg
TabletOral use10 mg
TabletOral use2.5 mg
TabletOral use5 mg
Tablet for suspensionoral2 mg
Tablet for suspensionoral3 mg
Tablet for suspensionoral5 mg
Tablet, for suspensionoral2 mg/1
Tablet, for suspensionoral3 mg/1
Tablet, for suspensionoral5 mg/1
Tabletoral0.25 mg
Tabletoral0.50 mg
Tabletoral0.75 mg
Dispersible tabletOral use2 mg
Dispersible tabletOral use3 mg
Dispersible tabletOral use5 mg
Tabletoral.25 mg/1
Tabletoral.5 mg/1
Tabletoral.75 mg/1
Prices
Unit descriptionCostUnit
Afinitor 10 mg tablet247.58USD tablet
Afinitor 5 mg tablet234.75USD tablet
Vesicare 10 mg tablet6.98USD tablet
Vesicare 5 mg tablet6.98USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2145383 No2004-11-162013-09-24Canada
CA2225960 No2004-05-112016-07-12Canada
US5665772 Yes2000-03-092020-03-09Us
US6004973 Yes1997-01-122017-01-12Us
US6239124 Yes1998-02-112018-02-11Us
US6440990 No1993-09-242013-09-24Us
US6455518 Yes1998-01-292018-01-29Us
US7297703 Yes2000-06-062020-06-06Us
US7741338 No1999-12-062019-12-06Us
US8410131 Yes2006-05-012026-05-01Us
US8436010 Yes2002-08-222022-08-22Us
US8617598 Yes2003-03-272023-03-27Us
US8778962 Yes2002-08-182022-08-18Us
US9006224 No2008-07-012028-07-01Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00163 mg/mLALOGPS
logP5.01ALOGPS
logP7.4ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area204.66 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity261.71 m3·mol-1ChemAxon
Polarizability106.61 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (87.7 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference
  1. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001038/WC500022817.pdf
General References
  1. Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA: Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001 Jun 7;44(12):2027-34. [PubMed:11384247 ]
  2. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671. [PubMed:21047224 ]
  3. den Burger JC, Wilhelm AJ, Chahbouni A, Vos RM, Sinjewel A, Swart EL: Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2012 Oct;404(6-7):1803-11. doi: 10.1007/s00216-012-6317-8. Epub 2012 Aug 17. [PubMed:22899246 ]
  4. Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ: Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol. 2013 May;71(5):1231-40. doi: 10.1007/s00280-013-2117-x. Epub 2013 Mar 3. [PubMed:23455452 ]
External Links
ATC CodesL01XE10L04AA18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (548 KB)
MSDSDownload (220 KB)
Interactions
Drug Interactions
Drug
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Everolimus.
AcetaminophenThe serum concentration of Everolimus can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Everolimus.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Everolimus.
AfatinibThe serum concentration of Everolimus can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Everolimus.
AlbendazoleThe serum concentration of Everolimus can be increased when it is combined with Albendazole.
AlectinibThe serum concentration of Everolimus can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Everolimus can be increased when it is combined with Alfentanil.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Everolimus.
AmantadineThe serum concentration of Everolimus can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Everolimus can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Everolimus can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Everolimus can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Everolimus can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Everolimus can be increased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Everolimus can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Everolimus can be increased when it is combined with Aprepitant.
AstemizoleThe serum concentration of Everolimus can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Everolimus can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Everolimus can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Everolimus can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Everolimus can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Everolimus can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Everolimus can be increased when it is combined with Azithromycin.
BenazeprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazepril.
BenzocaineThe serum concentration of Everolimus can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Everolimus can be increased when it is combined with Bepridil.
BevacizumabBevacizumab may increase the cardiotoxic activities of Everolimus.
BexaroteneThe serum concentration of Everolimus can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Everolimus can be increased when it is combined with Biperiden.
BoceprevirThe serum concentration of Everolimus can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Everolimus can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Everolimus can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Everolimus can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Everolimus can be increased when it is combined with Bromocriptine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Everolimus.
BuprenorphineThe serum concentration of Everolimus can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Everolimus can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Everolimus can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Everolimus can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Everolimus can be increased when it is combined with Canagliflozin.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Everolimus.
CandesartanThe serum concentration of Everolimus can be increased when it is combined with Candesartan.
CandoxatrilThe risk or severity of adverse effects can be increased when Everolimus is combined with Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Captopril.
CaptoprilThe serum concentration of Everolimus can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Everolimus can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Everolimus can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Everolimus can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Everolimus.
CeritinibThe serum concentration of Everolimus can be increased when it is combined with Ceritinib.
ChloroquineThe serum concentration of Everolimus can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Everolimus can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Everolimus can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Everolimus.
ChlorprothixeneThe serum concentration of Everolimus can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Everolimus can be increased when it is combined with Cholesterol.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Everolimus.
CilazaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Cilazapril.
CilazaprilThe serum concentration of Everolimus can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Everolimus can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Everolimus can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Everolimus can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Everolimus can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Everolimus can be decreased when combined with Clemastine.
ClofazimineThe serum concentration of Everolimus can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Everolimus can be increased when it is combined with Clomipramine.
ClotrimazoleThe metabolism of Everolimus can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Everolimus is combined with Clozapine.
CobicistatThe serum concentration of Everolimus can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Everolimus can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Everolimus can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Everolimus can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Everolimus can be decreased when combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Everolimus.
CyclosporineThe metabolism of Everolimus can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Everolimus can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Everolimus can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Everolimus can be increased when it is combined with Dactinomycin.
DarunavirThe serum concentration of Everolimus can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Everolimus can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Everolimus can be increased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Everolimus can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Everolimus can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Everolimus.
DesipramineThe serum concentration of Everolimus can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Everolimus.
DesloratadineThe serum concentration of Everolimus can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Everolimus can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Everolimus can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Everolimus can be increased when it is combined with Diclofenac.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Everolimus.
DigoxinDigoxin may decrease the cardiotoxic activities of Everolimus.
DihydroergotamineThe metabolism of Everolimus can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Everolimus can be decreased when combined with Diltiazem.
DipyridamoleThe serum concentration of Everolimus can be increased when it is combined with Dipyridamole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Everolimus.
DoxazosinThe serum concentration of Everolimus can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Everolimus can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Everolimus can be increased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Everolimus can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Everolimus can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Everolimus can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Everolimus.
EfavirenzThe serum concentration of Everolimus can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Everolimus can be increased when it is combined with Elbasvir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.
EnalaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Enalapril.
EnalaprilThe serum concentration of Everolimus can be increased when it is combined with Enalapril.
EnalaprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat.
EnzalutamideThe serum concentration of Everolimus can be decreased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Everolimus can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Everolimus can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Everolimus can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Everolimus can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Everolimus can be increased when it is combined with Estramustine.
EtoposideThe serum concentration of Everolimus can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Everolimus can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Everolimus.
FelodipineThe serum concentration of Everolimus can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Everolimus can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Everolimus can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Everolimus can be increased when it is combined with Fidaxomicin.
FingolimodEverolimus may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe metabolism of Everolimus can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of Everolimus can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Everolimus can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Everolimus can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Everolimus can be increased when it is combined with Flurazepam.
FluvoxamineThe metabolism of Everolimus can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Everolimus can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Everolimus can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.
FosphenytoinThe serum concentration of Everolimus can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Everolimus can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Everolimus can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Everolimus can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Everolimus.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Everolimus.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Everolimus.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Everolimus.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Everolimus.
GlyburideThe serum concentration of Everolimus can be increased when it is combined with Glyburide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Everolimus.
GlycerolThe serum concentration of Everolimus can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Everolimus can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Everolimus can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Everolimus can be increased when it is combined with Haloperidol.
HydrocortisoneThe serum concentration of Everolimus can be increased when it is combined with Hydrocortisone.
IdelalisibThe serum concentration of Everolimus can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Everolimus can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Everolimus can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Everolimus can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Everolimus can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Everolimus.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Everolimus.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Everolimus.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Everolimus.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Everolimus.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Everolimus.
IsavuconazoniumThe metabolism of Everolimus can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Everolimus can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Everolimus can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Everolimus can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Everolimus can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Everolimus can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Everolimus can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Everolimus can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Everolimus can be increased when it is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Everolimus is combined with Leflunomide.
LevofloxacinThe serum concentration of Everolimus can be increased when it is combined with Levofloxacin.
LidocaineThe serum concentration of Everolimus can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Everolimus.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Everolimus.
LisinoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Lisinopril.
LisinoprilThe serum concentration of Everolimus can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Everolimus can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Everolimus can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Everolimus can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Everolimus can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Everolimus can be increased when it is combined with Losartan.
LovastatinThe metabolism of Everolimus can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Everolimus can be increased when it is combined with Luliconazole.
MaprotilineThe serum concentration of Everolimus can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Everolimus can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Everolimus can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Everolimus can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Everolimus can be increased when it is combined with Meprobamate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Everolimus.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.
MethadoneThe serum concentration of Everolimus can be increased when it is combined with Methadone.
MetoprololThe serum concentration of Everolimus can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Everolimus can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Everolimus can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Everolimus can be increased when it is combined with Midazolam.
MifepristoneThe metabolism of Everolimus can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Everolimus.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Everolimus.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Everolimus.
MitomycinThe serum concentration of Everolimus can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Everolimus can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Everolimus can be increased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Everolimus can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.
MorphineThe serum concentration of Everolimus can be increased when it is combined with Morphine.
NafcillinThe serum concentration of Everolimus can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Everolimus can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Everolimus can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Everolimus.
NefazodoneThe serum concentration of Everolimus can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Everolimus can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Everolimus can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Everolimus can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Everolimus can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Everolimus can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Everolimus can be increased when it is combined with Nifedipine.
NilotinibThe metabolism of Everolimus can be decreased when combined with Nilotinib.
NisoldipineThe serum concentration of Everolimus can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Everolimus can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Everolimus can be increased when it is combined with Nitrendipine.
OlaparibThe metabolism of Everolimus can be decreased when combined with Olaparib.
OmapatrilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Omapatrilat.
OmeprazoleThe serum concentration of Everolimus can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Everolimus can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Everolimus.
P-NitrophenolThe serum concentration of Everolimus can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Everolimus can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Everolimus can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Everolimus can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Everolimus can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Everolimus can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Everolimus can be decreased when it is combined with Pentobarbital.
PerindoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Perindopril.
PerindoprilThe serum concentration of Everolimus can be increased when it is combined with Perindopril.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Everolimus.
PhenobarbitalThe serum concentration of Everolimus can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Everolimus can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Everolimus.
PimozideThe serum concentration of Everolimus can be increased when it is combined with Pimozide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Everolimus.
PonatinibThe serum concentration of Everolimus can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Everolimus can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Everolimus.
PravastatinThe serum concentration of Everolimus can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Everolimus can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Everolimus can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Everolimus can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Everolimus can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Everolimus can be increased when it is combined with Progesterone.
PromethazineThe serum concentration of Everolimus can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Everolimus can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Everolimus can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Everolimus can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Everolimus can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Everolimus can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.
QuinidineThe serum concentration of Everolimus can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Everolimus can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Everolimus is combined with Rabies vaccine.
RamiprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Ramipril.
RanitidineThe serum concentration of Everolimus can be increased when it is combined with Ranitidine.
RanolazineThe metabolism of Everolimus can be decreased when combined with Ranolazine.
ReboxetineThe serum concentration of Everolimus can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Everolimus can be increased when it is combined with Regorafenib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Everolimus.
RescinnamineThe risk or severity of adverse effects can be increased when Everolimus is combined with Rescinnamine.
ReserpineThe serum concentration of Everolimus can be increased when it is combined with Reserpine.
RifabutinThe serum concentration of Everolimus can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Everolimus can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Everolimus can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Everolimus can be increased when it is combined with Rilpivirine.
RitonavirThe serum concentration of Everolimus can be increased when it is combined with Ritonavir.
RoflumilastRoflumilast may increase the immunosuppressive activities of Everolimus.
RolapitantThe serum concentration of Everolimus can be increased when it is combined with Rolapitant.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Everolimus.
SaquinavirThe serum concentration of Everolimus can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Everolimus.
ScopolamineThe serum concentration of Everolimus can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Everolimus can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Everolimus can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Everolimus can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Everolimus can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Everolimus can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Everolimus can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Everolimus.
SirolimusThe serum concentration of Everolimus can be increased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Everolimus.
SorafenibThe serum concentration of Everolimus can be increased when it is combined with Sorafenib.
SpiraprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Spirapril.
SpironolactoneThe serum concentration of Everolimus can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Everolimus can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Everolimus can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Everolimus can be increased when it is combined with Stiripentol.
SulfinpyrazoneThe serum concentration of Everolimus can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Everolimus can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Everolimus.
SumatriptanThe serum concentration of Everolimus can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Everolimus can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Everolimus can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Everolimus.
TamoxifenThe serum concentration of Everolimus can be increased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Everolimus can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Everolimus can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Everolimus can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Everolimus can be increased when it is combined with Telmisartan.
TemocaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Temocapril.
TemsirolimusThe serum concentration of Everolimus can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Everolimus can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Everolimus can be increased when it is combined with Terfenadine.
TestosteroneThe serum concentration of Everolimus can be increased when it is combined with Testosterone.
TicagrelorThe serum concentration of Everolimus can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Everolimus can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Everolimus can be decreased when it is combined with Tocilizumab.
TofacitinibEverolimus may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Everolimus.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Everolimus.
TolvaptanThe serum concentration of Everolimus can be increased when it is combined with Tolvaptan.
TrandolaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Trandolapril.
TrastuzumabTrastuzumab may increase the neutropenic activities of Everolimus.
TrifluoperazineThe serum concentration of Everolimus can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Everolimus can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Everolimus can be increased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Everolimus can be increased when it is combined with Trimipramine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Everolimus.
TroleandomycinThe serum concentration of Everolimus can be increased when it is combined with Troleandomycin.
VenlafaxineThe metabolism of Everolimus can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Everolimus can be decreased when combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Everolimus.
VinblastineThe serum concentration of Everolimus can be increased when it is combined with Vinblastine.
VincristineThe serum concentration of Everolimus can be increased when it is combined with Vincristine.
VinorelbineThe serum concentration of Everolimus can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Everolimus.
VoriconazoleThe serum concentration of Everolimus can be increased when it is combined with Voriconazole.
ZimelidineThe serum concentration of Everolimus can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Everolimus can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM: Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Pediatr Transplant. 2008 Jun;12(4):456-63. doi: 10.1111/j.1399-3046.2007.00832.x. [PubMed:18466433 ]
  2. Rostaing L, Kamar N: mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol. 2010 Mar-Apr;23(2):133-42. [PubMed:20155724 ]
  3. George S, Bukowski RM: Role of everolimus in the treatment of renal cell carcinoma. Ther Clin Risk Manag. 2009 Oct;5(5):699-706. Epub 2009 Sep 15. [PubMed:19774211 ]
  4. Teachey DT, Grupp SA, Brown VI: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. [PubMed:19344392 ]
  5. Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E: New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. [PubMed:20569080 ]
  6. Coppin C: Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics. 2010 May 25;4:91-101. [PubMed:20531964 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 09:37 / Updated on September 30, 2016 03:38